News
-
-
-
COMMUNIQUÉ DE PRESSE
G.ST Antivirals reports start of Phase II trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer
G.ST Antivirals starts Phase II trial and appoints Ronald Bruce Turner as new Chief Medical Officer. Trial aims to assess effectiveness of novel antiviral nasal spray against respiratory viruses -
COMMUNIQUÉ DE PRESSE
G.ST Antivirals reports positive Phase I trial results for 2-Deoxy-D-glucose against upper respiratory infections
G.ST Antivirals reports positive Phase I trial results for 2-Deoxy-D-glucose (2-DG) against upper respiratory infections and secures over EUR 6 million for Phase II clinical trial. The intranasal administration of 2-DG was found to be safe, well tolerated, and did not lead to any serious adverse events (SAEs). The compound targets rhinoviruses and coronaviruses, offering potential broad-spectrum antiviral treatment against respiratory tract infections. The successful financing round includes a EUR 4 million Series A funding led by xista science ventures (xsv), with additional commitment from the Life Sciences Programme of the Austrian Research Promotion Agency (FFG). G.ST Antivirals, a spin-off from the Medical University of Vienna, is on track to advance its innovative drug against colds and other viral infections, with the Phase II clinical trial set to commence in the first half of 2024.
